Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 1/20 | 0.62 |
| ▸ | HTR2B | P41595 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.60 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 4/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10023024 | 1.00 | HTR2A (0.62) | HTR2AHTR2CHTR2BSIGMAR1TAAR1 | |
| SCHEMBL29602616 | 1.00 | HTR2A (0.62) | HTR2AHTR2CHTR2BSIGMAR1TAAR1 | |
| SCHEMBL16552400 | 0.85 | MAOB (0.56) | HTR2AHTR2CHTR2BSIGMAR1TAAR1 | |
| SCHEMBL15133588 | 0.82 | HTR1B (0.54) | SIGMAR1TAAR1SLC18A2HTR1BADRB2 | |
| SCHEMBL3677922 | 0.80 | HTR2A (0.71) | HTR2AHTR2CHTR2BSIGMAR1ADRB2 | |
| SCHEMBL8694702 | 0.80 | HTR2A (0.56) | HTR2AHTR2CHTR2BSIGMAR1ADRB2 | |
| SCHEMBL23023142 | 0.80 | SIGMAR1 (0.69) | HTR2AHTR2CHTR2BSIGMAR1ADRB2 | |
| SCHEMBL27922311 | 0.78 | ACACB (0.73) | HTR2AHTR2CHTR2BSIGMAR1ADRB2 | |
| SCHEMBL27922312 | 0.78 | ACACB (0.73) | HTR2AHTR2CHTR2BSIGMAR1ADRB2 | |
| Hydrochloric Acid SCHEMBL26983843 | 0.77 | HTR1B (0.56) | SIGMAR1TAAR1SLC18A2HTR1BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097266-A1 | Bombesin Analog Peptide Antagonist Conjugates | BRS3, VIP, GRPR | HTR2A 3312/4885HTR2C 3659/4885HTR2B 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.